

DIN ISO 13022:2014-06 (E)

Medical products containing viable human cells - Application of risk management and requirements for processing practices (ISO 13022:2012)

Contents	Page
National foreword	3
National Annex NA (informative) Correction of Figure B.1	4
National Annex N (informative) Bibliography	5
Introduction	6
1 Scope	7
2 Normative references	8
3 Terms and definitions	8
4 Risk management process	12
4.1 General	12
4.2 Hazards associated with the cellular component	12
4.3 Risk analysis	14
4.4 Risk evaluation	15
4.5 Risk control	15
4.6 Evaluation of overall residual risk acceptability	15
4.7 Production and post-production information system	16
Annex B (informative) Graphic representation of the part of the risk management process for cell-based medical products	18
Annex C (normative) Requirements for donor selection and testing	19
Annex D (informative) Guidance for tissue procurement	23
Annex E (normative) Requirements for handling of cells and tissue during manufacture	26
Annex F (normative) Requirements for packaging and labelling	29
Annex G (informative) Guidance for transport	32
Annex H (informative) Guidance for storage	37
Annex I (normative) Requirements for traceability	40
Annex J (normative) Risk reduction measures related to contamination with viruses and other infectious agents such as TSE	41
Annex K (informative) Guidance with regard to hazards caused by the tumorigenic potential of the human cells/tissues used for the production of medical products	44
Annex L (informative) Guidance with regard to microbiological contamination	45
Annex M (informative) Guidance with regard to potential adverse effects of non-cellular residues of the product	46

Annex N (normative) Requirements with regard to potential adverse effects of the cellular components of a medical product	47
Annex O (informative) Guidance for the characterization of the cellular components of a medical product	48
Annex P (informative) Clinical evaluation and testing	51
Bibliography	52